In this GEN webinar, our expert speakers will explore cutting-edge drug discovery techniques for target deconvolution and multiplex target discovery.

Poster presentation highlights promising results from Phase 1b/2 TENACITY-01 study of CTD402 in T-Cell and myeloid leukemiasFindings underscore ...

TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed AML ...

"Our significant showcase at ASH this year reflects Parexel’s specialized scientific and medical expertise in hematology and our commitment to partnering with leading biopharma sponsors to advance ...

The Life Sciences BPO Market is expanding rapidly, driven by rising R&D costs, increasing regulatory complexities and the growing need for operational efficiency across pharma and biotech sectors.

Discover why Structure Therapeutics Inc. is rated Strong Buy after positive Aleniglipron phase 2b obesity data. Click for ...

Nigeria becomes the 24th out of only 25 NRAs worldwide recognised for commitment to globally harmonised pharmaceutical standards ...

The Global Life Sciences BPO Market Size projected to grow at a CAGR of 7.50% from 2026 to 2032, according to a new report published by Verified Market Research®. The report reveals that the market ...

While pharmaceutical companies face some of the most stringent product marketing requirements in the US, the regulatory ...

Citi Annual Global Healthcare Conference 2025 December 3, 2025 4:00 PM ESTCompany ParticipantsMarshall Fordyce - ...

Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today presented clinical data for CTD402, its investigational allogeneic anti-CD7 CAR ...

An updated Canadian guideline on HIV prevention addresses the expanding range of medications available to reduce the risk of ...